Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model

International Journal of Cancer

Volumn 125, Issue 3, 2009, Pages 698-707

  Chuang, Tien Fu ^a   Lee, Shan Chih ^b   Liao, Kuang Wen ^a   Hsiao, Ya Wen ^a   Lo, Chia Hui ^c   Chiang, Bor Luen ^d   Lin, Xi Zhang ^e   Tao, Mi Hua ^b,c   Chu, Rea Min ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Canine transmissible venereal tumor; Electroporation; Gene therapy; IL 12; Intratumoral

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; LIPOCORTIN 5; LUCIFERASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANIMAL VENEREAL TUMOR; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MODEL; CANINE TRANSMISSIBLE VENEREAL TUMOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOG; ELECTRODE; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE THERAPY; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR REGRESSION;

ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; ELECTROCHEMOTHERAPY; FLOW CYTOMETRY; GENE THERAPY; GENES, MHC CLASS I; GENES, MHC CLASS II; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-12; NEOPLASM TRANSPLANTATION; VENEREAL TUMORS, VETERINARY;

EID: 67650065521     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24418     Document Type: Article

References (55)

1. Kirkness EF, Bafna V, Halpern AL, Levy S, Remington K, Rusch DB, Delcher AL, Pop M, Wang W, Fraser CM, Venter JC. The dog genome: survey sequencing and comparative analysis. Science 2003;301:1898-903.
2. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990;9:125-36.
3. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000;18:781-92.
4. White GA. Transmissible venereal tumor in a dog. Vet Med Small Anim Clin 1976;71:299-301.
5. Albanese F, Poli A, Millanta F, Abramo F. Primary cutaneous extragenital canine transmissible venereal tumour with Leishmania-laden neoplastic cells: a further suggestion of histiocytic origin? Vet Dermatol 2002;13:243-6.
6. Katzir N, Arman E, Cohen D, Givol D, Rechavi G. Common origin of transmissible venereal tumors (TVT) in dogs. Oncogene 1987;1:445-8.
7. Liao KW, Lin ZY, Pao HN, Kam SY, Wang FI, Chu RM. Identification of canine transmissible venereal tumor cells using in situ polymerase chain reaction and the stable sequence of the long interspersed nuclear element. J Vet Diagn Invest 2003;15:399-406.
8. Murgia CPJ, Kim SY, Fassati A, Weiss RA. Clonal origin and evolution of a transmissible cancer. Cell 2006;126:477-87.
9. Chu RM, Sun TJ, Yang HY, Wang DG, Liao KW, Chuang TF, Lin CH, Lee WC. Heat shock proteins in canine transmissible venereal tumor. Vet Immunol Immunopathol 2001;82:9-21.
10. Chu RM, Lin CY, Liu CC, Yang SY, Hsiao YW, Hung SW, Pao HN, Liao KW. Proliferation characteristics of canine transmissible venereal tumor. Anticancer Res 2001;21:4017-24.
11. Hess A, Cunningham B, Taylor Bennett B, Epstein R. In vitro correlates of the in vivo course of the canine transmissible venereal tumor studied by mixed lymphocyte-tumor cultures. Transplant Proc 1975;7:507-11.
12. Hsiao YW, Liao KW, Hung SW, Chu RM. Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Vet Immunol Immunopathol 2002;87:19-27.
13. Hsiao YW, Liao KW, Chung TF, Liu CH, Hsu CD, Chu RM. Interactions of host IL-6 and IFN-gamma and cancer-derived TGF-beta1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol Immunother 2008;57:1091-104.
14. Hsiao YW, Liao KW, Hung SW, Chu RM. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J Immunol 2004;172:1508-14.
15. Liu CC, Wang YS, Lin CY, Chuang TF, Liao KW, Chi KH, Chen MF, Chiang HC, Chu RM. Transient downregulation of monocytederived dendritic-cell differentiation, function, and survival during tumoral progression and regression in an in vivo canine model of transmissible venereal tumor. Cancer Immunol Immunother 2008;57:479-91.
16. Liao KW, Hung SW, Hsiao YW, Bennett M, Chu RM. Canine transmissible venereal tumor cell depletion of B lymphocytes: molecule(s) specifically toxic for B cells. Vet Immunol Immunopathol 2003;92:149-62.
17. Barber MR, Yang TJ. Tumor infiltrating lymphocytes: CD8+ lymphocytes in canine transmissible venereal sarcomas at different stages of tumor growth. Anticancer Res 1999;19:1137-42.
18. Hsiao YW, Liao KW, Hung SW, Chu RM. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta1 and restores the lymphokine-activated killing activity. J Immunol 2004;172:1508-14.
19. Lin CY, Chuang TF, Liao KW, Huang YJ, Pai CC, Chu RM. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Cancer Lett 2008;272:285-95.
20. Chou PC, Chuang TF, Jan TJ, Gion HC, Huang YC, Lei HJ, Chen WY, Chu RM. Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in Beagles. Vet Immunol Immunopathol, in press.
21. Kanagawa N, Gao JQ, Motomura Y, Yanagawa T, Mukai Y, Yoshioka Y, Okada N, Nakagawa S. Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor. Biochem Biophys Res Commun 2008;372:821-5.
22. Pignata C, Sanghera JS, Cossette L, Pelech SL, Ritz J. Interleukin-12 induces tyrosine phosphorylation and activation of 44-kD mitogenactivated protein kinase in human T cells. Blood 1994;83:184-90.
23. Zhang C, Zhang J, Niu J, Zhou Z, Tian Z. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum Immunol 2008;69:490-500.
24. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007;13:4677-85.
25. Airoldi I, Di Carlo E, Cocco C, Taverniti G, D'Antuono T, Ognio E, Watanabe M, Ribatti D, Pistoia V. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci USA 2007;104:3996-4001.
26. Maruyama K, Takigawa Y, Akiyama Y, Hojo T, Nara-Ashizawa N, Cheng JY, Watanabe M, Yamaguchi K. Structure and characterization of hamster IL-12 p35 and p40. Mol Immunol 2003;40:319-26.
27. Maruo S, Oh-hora M, Ahn HJ, Ono S, Wysocka M, Kaneko Y, Yagita H, Okumura K, Kikutani H, Kishimoto T, Kobayashi M, Hamaoka T, et al. B cells regulate CD40 ligand-induced IL-12 production in antigen-presenting cells (APC) during T cell/APC interactions. J Immunol 1997;158:120-6.
28. Elzaouk L, Moelling K, Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 2006;15:865-74.
29. Tros De Ilarduya C, Bunuales M, Qian C, Duzgunes N. Antitumoral activity of transferrin-lipoplexes carrying the IL-12 gene in the treatment of colon cancer. J Drug Target 2006;14:527-35.
30. Faggioli F, Soldati S, Scanziani E, Cato EM, Adorni F, Vezzoni P, Noonan DM, Sacco MG. Effects of IL-12 gene therapy on spontaneous transgenic and transplanted breast tumors. Breast Cancer Res Treat 2008;110:223-6.
31. Dean DA, Machado-Aranda D, Blair-Parks K, Yeldandi AV, Young JL. Electroporation as a method for high-level nonviral gene transfer to the lung. Gene Ther 2003;10:1608-15.
32. Tupin E, Poirier B, Bureau MF, Khallou-Laschet J, Vranckx R, Caligiuri G, Gaston AT, Duong Van Huyen JP, Scherman D, Bariety J, Michel JB, Nicoletti A. Non-viral gene transfer of murine spleen cells achieved by in vivo electroporation. Gene Ther 2003;10:569-79.
33. Pavlin D, Tozon N, Sersa G, Pogacnik A, Cemazar M. Efficient electrotransfection into canine muscle. Technol Cancer Res Treat 2008;7:45-54.
34. Yano K, Ide K, Momoi Y, Yamazoe K, Kudo T. Enhancement of reactive oxygen species production from canine blood leukocytes by human recombinant interleukin-12. Vet Immunol Immunopathol 2003;93:1-8.
35. Phillips BS, Padilla ML, Dickerson EB, Lindstrom MJ, Helfand SC. Immunostimulatory effects of human recombinant interleukin-12 on peripheral blood mononuclear cells from normal dogs. Vet Immunol Immunopathol 1999;70:189-201.
36. Lieschke GJ, Rao PK, Gately MK, Mulligan RC. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 1997;15:35-40.
37. Lee SM, Suen Y, Qian J, Knoppel E, Cairo MS. The regulation and biological activity of interleukin 12. Leuk Lymphoma 1998;29:427-38.
38. Liu CC, Wang YS, Lin CY, Chuang TF, Liao KW, Chi KH, Chen MF, Chiang HC, Chu RM. Transient downregulation of monocytederived dendritic-cell differentiation, function, and survival during tumoral progression and regression in an in vivo canine model of transmissible venereal tumor. Cancer Immunol Immunother 2008;57:479-91.
39. Macgregor JN, Li Q, Chang AE, Braun TM, Hughes DP, McDonagh KT. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin. Cancer Res 2006;66:4913-21.
40. Eguchi J, Hiroishi K, Ishii S, Mitamura K. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing. Cancer Immunol Immunother 2003;52:378-86.
41. Walser TC, Ma X, Kundu N, Dorsey R, Goloubeva O, Fulton AM. Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model. J Immunother 2007;30:490-8.
42. Li S, Xia X, Mellieon FM, Liu J, Steele S. Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy. Mol Ther 2004;9:347-54.
43. Li S, Zhang L, Torrero M, Cannon M, Barret R. Administration routeand immune cell activation-dependent tumor eradication by IL12 electrotransfer. Mol Ther 2005;12:942-9.
44. Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 2006;118:6-10.
45. Zhao M, Flynt FL, Hong M, Chen H, Gilbert CA, Briley NT, Bolick SC, Wright KL, Piskurich JF. MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma. Mol Immunol 2007;44:2923-32.
46. Naoe M, Marumoto Y, Aoki K, Fukagai T, Ogawa Y, Ishizaki R, Nakagami Y, Yoshida H, Ballo M. MHC-class I expression on prostate carcinoma and modulation by IFN-gamma. Nippon Hinyokika Gakkai Zasshi 2002;93:532-8.
47. Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, Turley H, Dobbs N, Gatter K, Talbot DC, Harris AL, Ganesan TS. Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res 2003;9:84-92.
48. Lin CY, Chuang TF, Liao KW, Huang YJ, Pai CC, Chu RM. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Cancer Lett 2008;272:285-95.
49. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000;165:2665-70.
50. Yamashita YI, Shimada M, Hasegawa H, Minagawa R, Rikimaru T, Hamatsu T, Tanaka S, Shirabe K, Miyazaki JI, Sugimachi K. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 2001;61:1005-12.
51. Tare NS, Bowen S, Warrier RR, Carvajal DM, Benjamin WR, Riley JH, Anderson TD, Gately MK. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J Interferon Cytokine Res 1995;15:377-83.
52. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997;90:2541-8.
53. Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995;270:908.
54. Schultz J, Pavlovic J, Strack B, Nawrath M, Moelling K. Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA. Hum Gene Ther 1999;10:407-17.
55. Cutrera J, Torrero M, Shiomitsu K, Mauldin N, Li S. Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. Methods Mol Biol 2008;423:319-25.